Hammad

FCPS (Med and Clinical Haem),
MRCP UK, DRCPath,
FRCPath Haematology UK
dad, physician and expert procrastinator
#LearnAndRelearn

[Benlazar S M A @smbenlazar]

Maintenance Therapy in Acute Myeloid Leukemia: Current Perspectives and Future Directions https://t.co/9vUiPq98pB #mdpicurroncol via @CurrentOncology #AML #leusm

[Haematologica @Haematologica]

Landmark Paper: in 2012, J.P. Patel and colleagues reported in the NEJM a milestone comprehensive molecular analysis that continues to shape modern AML management
https://t.co/1gI2tCzQGG

[Ahmed Kotb @AhmedKo45911157]

Acute leukemia of ambiguous lineage: the known and the uncertain
https://t.co/aQXyOzYSK4

[Nikolas Spyrou @NikolaSpyrouMD]

Azacytidine, our fantastic hypomethylating agent, used for treatment of MDS and AML, was discovered in 1964, and then fell into oblivion. Almost 40 years later it was FDA approved as the first effective MDS treatment.

A 🧵about an unusual revival:

[Hammad @Hammad2286]

@sebas_arruarana @American_Heart That's great
[email protected]
Regards

[GvHD Hub @gvhd_hub]

CONGRESS | #IACH | PRESENTATION
Maria Helena Parrinello @Emmeaccapi, San Raffaele Hospital, presents a case study of a patient with cGvHD and new-onset dysphagia. Parrinello highlights the importance of long-term monitoring for detection of secondary malignancies after HSCT.
Follow our live feed for more updates: https://t.co/vNwqmO0Rzb
Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content. A full list of supporters can be found on our website.
#GvHD #GvHDsm #MedicalCongress

[Hammad @Hammad2286]

@TheIACH @Mohty_EBMT Thnx for the wonderful talk
Is it possible to get the slides of this ppt?

[Hammad @Hammad2286]

4/4

In other words, KPC is one of the mechanisms by which certain CRE bacteria achieve carbapenem resistance. Not all CRE produce KPC; some may use other carbapenemase enzymes or different resistance mechanisms. KPC-producing CRE is a subset of CRE and is notably common in US

[Hammad @Hammad2286]

1/X
What is difference bw CRE and KPC microbes

The key difference between CRE and KPC microbes lies in their definitions and relationship:

[Hammad @Hammad2286]

3/X
- KPC (Klebsiella pneumoniae carbapenemase) is a specific enzyme produced by some CRE bacteria. KPC breaks down carbapenems, making these antibiotics ineffective against the bacteria.

[Hammad @Hammad2286]

Response assessment in #AML

[Hammad @Hammad2286]

2/2

❌ Resistant / Poor Responders:
- Monocytic AML (M4/M5, esp. mature/secondary type)
- TP53-mutated AML
- FLT3-ITD / TKD mutations
- RAS pathway mutations (NRAS, KRAS, PTPN11)
- KMT2A (MLL) rearranged AML
- Complex karyotype AML
- Secondary AML from MDS/MPN

#AML

[Hammad @Hammad2286]

📌 AML Response to Venetoclax (VEN)

✅ Good Responders:
- NPM1-mutated AML
- IDH1 / IDH2-mutated AML
- RUNX1-mutated AML (some cases)
- De novo AML without adverse genetics

1/2
#AML

[Hammad @Hammad2286]

@nihardesai89 @ASH_hematology @DrAkhilX @BrownJHM @VJHemOnc @MorphologyAmigo @VaqueraH_md @TheEBMT_Trainee @DrNikitaMehra @rudra09s025 @GonzaloBentoli1 Copper deficiency or Zinc toxicity

[Dr. Chokri Ben Lamine @abouabdrahman0]

🧪 Thiotepa in Conditioning — MAC vs RIC

⸻

🔥 Myeloablative Conditioning (MAC)
•Thiotepa 10 mg/kg (single dose) OR 5 mg/kg ×2 (total 10 mg/kg) 💥
•Often combined with 🧬 Busulfan, Fludarabine, ATG, TBI
•Goal = full marrow ablation 🦴❌

⸻

🌿 Reduced-Intensity Conditioning (RIC)
•Thiotepa 5 mg/kg (single dose) OR 2.5 mg/kg ×2 (total 5 mg/kg) 🌱
•Combined with Fludarabine ± Melphalan/Treosulfan
•Goal = immunosuppression > ablation (engraftment with less toxicity)

⸻

📌 Key Pearl
👉 Dose intensity = main difference: 10 mg/kg = MAC 💥, 5 mg/kg = RIC 🌿
👉 Adjust per protocol, disease, age, comorbidity, donor type.

#SOHO25 #BMT #Conditioning #Thiotepa #HCT

[Hammad @Hammad2286]

@faheema_hasan ETP ALL

[Hammad @Hammad2286]

@faheema_hasan High grade lymphoma in leukemic Phase

[Talha Badar @TalhaBadarMD]

Ruxolitinib combined with dexamethasone for adult patients with newly diagnosed hemophagocytic lymphohistiocytosis in China https://t.co/MRlggOQm7n

The Ru-D regimen was well tolerated, resulting in OS rates of 85.7%, 67.9%, and 53.6% at 2 months, 6 months, and 2 years, respectively. #HLH @BloodPortfolio